Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate

Transfusion

Volumn 45, Issue 7, 2005, Pages 1214-1220

  Perseghin, Paolo ^a   Gambacorti Passerini, Carlo ^b   Tornaghi, Lucia ^b   Dassi, Maria ^b   Pioltelli, Pietro ^b   Parma, Matteo ^b   Colnaghi, Federica ^b   Giudici, Giovanni ^b   Elli, Elena ^b   Fumagalli, Monica ^b   Ponchio, Luisa ^b   Biondi, Andrea ^b   Pogliani, Enrico M ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; HYDROXYUREA; IMATINIB; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; APHERESIS; ARTICLE; CD34 SELECTION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COMPLETE CYTOGENETIC RESPONSE; CYTOGENETICS; DISEASE DURATION; DOSE RESPONSE; FEMALE; HLA MATCHING; HUMAN; MALE; PERIPHERAL BLOOD STEM CELL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POLYMERASE CHAIN REACTION;

ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; BLOOD COMPONENT REMOVAL; CELL SURVIVAL; CELLS, CULTURED; CHROMOSOME BANDING; COLONY-FORMING UNITS ASSAY; CYTOGENETIC ANALYSIS; FEASIBILITY STUDIES; FILGRASTIM; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LYMPHOCYTE COUNT; PIPERAZINES; PYRIMIDINES; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 21644436163     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2005.00175.x     Document Type: Article

References (21)

1. Melo JV. The molecular biology of chronic myeloid leukemia. Leukemia 1996;10:751-6.
2. Jahagirdar BN, Miller JS, Shet A, Verfaillie CM. Novel therapies for chronic myelogenous leukemia. Exp Hematol 2000;29:543-56.
3. Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 2003;349:1449-62.
4. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52.
5. Goldman JM. Chronic myeloid leukemia - still a few questions. Exp Hematol 2004;32:2-10.
6. Stentoft J, Pallisgard N, Kjeldsen E, et al. Kinetics of bcr-abl fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction. Hur J Haematol 2001;67:302-8.
7. Le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000; 95:1758-66.
8. Gorre LE, Mohammed M, Ellwood K, et al. Clinical resistance to STI571 cancer therapy caused by bcr-abl gene mutation or amplification. Science 2001;293:876-80.
9. Gambacorti-Passerini C, Gunby RH, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukemias. Lancet Oncol 2003;4:75-85.
10. Hui CH, Goh KY, Brandford S, et al. Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. Leukemia 2003;17:821-8.
11. Drummond MW, Marin D, Clarck RE, et al. Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukemia patients with imatinib mesylate-induced complete cytogenetic response. Br J Haematol 2003;123:479-83.
12. Kreuzer KA, Klühs C, Baskaynak G, et al. Filgrastim-induced stem cell mobilization in chronic myeloid leukemia patients during imatinib therapy: safety, feasibility and evidence for an efficient in vivo purging. Br J Haematol 2004;124:195-9.
13. Van Dongen JJM, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for the detection of minimal residual disease. Leukemia 1999; 13:1901-28.
14. Ponchio L, Eaves C, Hogge D, et al. Both cycling and noncycling primitive progenitors continue to be mobilized into the circulation during the leukapheresis of patients pretreated with chemotherapy and G-CSF. Br J Haematol 1997;99:394-402.
15. Carella AM, Beltrami G, Corsetti MT. Autografting in chronic myeloid leukemia. Sem Hematol 2003;40:72-8.
16. Gambacorti-Passerini C, le Coutre P, Mologni L, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997;23:380-94.
17. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928-37.
18. Neumann F, Herold C, Hildebrand B, et al. Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation. Eur J Haematol 2003;70:1-10.
19. Rosti G, Martinelli G, Bassi S, et al. Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood 2004;103:2284-90.
20. Bartolovic K, Balabanov S, Hartmann U, et al. Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 2004;103:523-9.
21. Sneed TB, Kantarjian HM, Talpaz M, et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 2004;100:116-21.